These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9504179)

  • 1. Risk factors for hepatotoxicity induced by antituberculosis drugs.
    Devoto FM; González C; Iannantuono R; Serra HA; González CD; Sáenz C
    Acta Physiol Pharmacol Ther Latinoam; 1997; 47(4):197-202. PubMed ID: 9504179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
    Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
    Schaberg T; Rebhan K; Lode H
    Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxicity of antitubercular agents for the liver].
    Dölle W
    Dtsch Med Wochenschr; 1973 Jan; 98(2):74. PubMed ID: 4683834
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse effects of antituberculosis drugs.
    Girling DJ
    Drugs; 1982; 23(1-2):56-74. PubMed ID: 6459920
    [No Abstract]   [Full Text] [Related]  

  • 11. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver injury during antituberculosis treatment: an 11-year study.
    Døssing M; Wilcke JT; Askgaard DS; Nybo B
    Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis.
    Bai H; Wu T; Jiao L; Wu Q; Zhao Z; Song J; Liu T; Lv Y; Lu X; Ying B
    J Clin Pharmacol; 2020 Mar; 60(3):361-368. PubMed ID: 31648372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.